Skip to main content
Premium Trial:

Request an Annual Quote

Canine Genetics Firm Embark Veterinary Raises $75M in Series B Round

NEW YORK — Embark Veterinary, which sells consumer DNA tests for dogs, said on Monday that it has raised $75 million in Series B funding.

The round was led by SoftBank Vision Fund 2 and included participation from previous investors F-Prime Capital, SV Angel, Slow Ventures, Freestyle Capital, and Third Kind Venture Capital.

Embark's test analyzes 200,000 genetic markers to provide owners and breeders with information about their dogs' breed, ancestry, health, and disease risk. The Boston-based company, which raised $10 million in a Series A round in early 2019, said it will use the new funding to accelerate the development of its discovery engine to expand its canine genetics database.

Competitors to Embark include Mars Petcare's Wisdom Health, OptiGen, and Paw Print Genetics.

The Scan

Transplant Tests Edited Pig Kidneys

The Associated Press reports a University of Alabama-Birmingham team transplanted genetically modified pig kidneys into a brain-dead human patient.

UK Changes Some Gene-Edited Crop Rules

A new law may enable gene-edited crops to be sold in the UK within about five years, New Scientist says.

Pill Works Against Omicron in Lab

Pfizer's antiviral pill to treat SARS-CoV-2 appears to work against the Omicron variant, the Wall Street Journal reports.

Nature Papers Find Genetic Risk Factor for Smell, Taste Loss in COVID-19; Analyze TB Granulomas

In Nature this week: genome-wide association study find locus linked to the risk COVID-19 patients losing their sense of taste or smell, and more.